Phase 1 Opioid Clinical Trials
13 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–13 of 13 trials
Recruiting
Phase 1Phase 2
Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids
Opioid-Induced Constipation (OIC)
Shionogi24 enrolled16 locationsNCT05588323
Recruiting
Phase 1Phase 2
Clinical Trials of Multivalent Opioid Vaccine Components
Opioid-use Disorder
New York State Psychiatric Institute45 enrolled2 locationsNCT04458545
Recruiting
Phase 1
Nalmefene Implant in Healthy Subjects
Opioid Abuse and Addiction
ReacX Pharmaceuticals, Inc.24 enrolled1 locationNCT07325279
Recruiting
Phase 1Phase 2
ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain
Chronic PainOpioid Withdrawal
Medical University of South Carolina240 enrolled1 locationNCT06442566
Recruiting
Phase 1
MethaLoad Dose-Finding Study
Opioid Use Disorder (OUD)
University of Pennsylvania24 enrolled1 locationNCT06877858
Recruiting
Phase 1
A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.
Multiple SclerosisOpioid DependenceAlcohol Dependence
Inventage Lab., Inc.40 enrolled1 locationNCT05620940
Recruiting
Phase 1Phase 2
Sleep Disordered Breathing With Opioid Use
Opioid UseSleep Apnea
VA Office of Research and Development150 enrolled1 locationNCT05589753
Recruiting
Phase 1
Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists
Opioid Induced Respiratory DepressionChronic Opioid Use
Leiden University Medical Center24 enrolled1 locationNCT05338632
Recruiting
Phase 1Phase 2
Ketamine Assisted Psychotherapy for Opioid Use Disorder
Opioid-use Disorder
University of Utah60 enrolled1 locationNCT04892251
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of (2S)-2-[17-(cyclopropylmethyl)-4, 5a-epoxy-3-hydroxy-6-methoxy-6a, 14-ethano-14a-morphinan-7a-yl]-3, 3-dimethylbutan-2-ol transdermal patch against the innovator (2S)-2-[17-(cyclopropylmethyl)-4, 5a-epoxy-3-hydroxy-6-methoxy-6a, 14-ethano-14a-morphinan-7a-yl]-3, 3-dimethylbutan-2-ol transdermal patch conducted under fasting conditions with the inclusion of a naltrexone block in healthy male and female volunteers
(2S)-2-[17-(cyclopropylmethyl)-4, 5a-epoxy-3-hydroxy-6-methoxy-6a, 14-ethano-14a-morphinan-7a-yl]-3, 3-dimethylbutan-2-ol is a partial opioid agonist indicated for the management of severe pain.
Zenith Technology Corporation Limited26 enrolled1 locationACTRN12622000133730
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 5/2.5 mg s 4,5a-epoxy14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride/naloxone tablet against the innovator 5/2.5 mg s 4,5a-epoxy14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride/naloxone tablet conducted under fasting conditions in healthy volunteers.
5/2.5 mg s 4,5a-epoxy14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride/naloxone belongs to a class of medicines called opioid analgesics and is prescribed for the relief of severe pain.
Zenith Technology Corporation Limited26 enrolled1 locationACTRN12620000327987
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of buprenorphine transdermal patch against the innovator buprenorphine transdermal patch conducted under fasting conditions and at steady state with the inclusion of a naltrexone block in healthy male and female volunteers
Buprenorphine is a partial opioid agonist indicated for the management of moderate to severe pain.
Zenith Technology Corp Ltd32 enrolled1 locationACTRN12616000600448
Completed
Phase 1
Noribogaine Therapy for Relief of Opioid withdrawal, Phase 1B
Symptoms of opioid withdrawal
DemeRx Inc27 enrolled1 locationACTRN12613001064796